The European Commissions simplification package is being debated almost entirely as an MDR story. The IVDR provisions carry ...

We’ve all heard the rhetorical question, “Who owns quality?” And we all reply with the answer they expect to hear: “We all do!” This mindset needs to be fully integrated into the minds and systems of ...

Implement AI in quality workflows without regulatory risk. Learn how strong governance and clear validation keep you ...

Navigate essential biotech and pharma regulations safely. Learn how unifying global standards streamlines audits and ...

For years, Chile has occupied a strange position in Latin American medtech strategy. It was sophisticated, stable, commercially attractive, and comparatively easy to enter. For many medical device ...

Scaling biopsy device manufacturing from prototype to high-volume production presents complex engineering and operational hurdles. Slight variations in raw materials or individual components compound ...

The intersection of healthcare and software engineering has fundamentally transformed the life sciences industry. Software is no longer merely a supportive tool; it is increasingly the primary ...

A structural engineer who has spent years studying how bridges fail is not the same as one who has only studied how they're built; both can read a blueprint, but one of them reads it differently. The ...

Medical device manufacturers with regulatory plans in Latin America often treat translation as a procurement task. Send the instructions for use (IFU), labeling, protocol, investigator brochure, or ...

One data point deserves more attention than the revenue: Novo reports that roughly 80% of pill users are new to GLP-1 therapy rather than switchers from the injection. 5 The tablet did not cannibalize ...

The operational realities of artificial intelligence governance in life science manufacturing demand immediate attention following recent regulatory actions. Relying on automated tools without human ...

Bridging the gap between a successful point-of-care (POC) assay prototype and full-scale commercialization requires early strategic alignment across design, chemistry, and high-volume production.